EUVIMEDEUVIMED entdecken
Crossref

4271 TREAT TO TARGET: NEOADJUVANT ANTI-OBESITY MEDICATION USE IS ASSOCIATED WITH INCREASED ONE-YEAR POSTOPERATIVE WEIGHT LOSS

Surgery for Obesity and Related Diseases · 2026-04 · 22 (4) · S15

DOI: 10.1016/j.soard.2026.02.059 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Surgery for Obesity and Related Diseases, 2026-04.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Zitieren

APA

(2026). 4271 TREAT TO TARGET: NEOADJUVANT ANTI-OBESITY MEDICATION USE IS ASSOCIATED WITH INCREASED ONE-YEAR POSTOPERATIVE WEIGHT LOSS. Surgery for Obesity and Related Diseases, 22(4), S15. https://doi.org/10.1016/j.soard.2026.02.059

Vancouver

4271 TREAT TO TARGET: NEOADJUVANT ANTI-OBESITY MEDICATION USE IS ASSOCIATED WITH INCREASED ONE-YEAR POSTOPERATIVE WEIGHT LOSS. Surgery for Obesity and Related Diseases. 2026;22(4):S15. doi:10.1016/j.soard.2026.02.059

BibTeX
@article{euvimed2026,
  title = {4271 TREAT TO TARGET: NEOADJUVANT ANTI-OBESITY MEDICATION USE IS ASSOCIATED WITH INCREASED ONE-YEAR POSTOPERATIVE WEIGHT LOSS},
  journal = {Surgery for Obesity and Related Diseases},
  year = {2026},
  volume = {22},
  number = {4},
  pages = {S15},
  doi = {10.1016/j.soard.2026.02.059}
}
Kostenlos starten →